2 Healthcare Names That Could Get a Big Boost From Earnings

Abbott reported Q3 FY2025 EPS of $1.30, in line with estimates, while missing revenue by just over $31 million as sales rose ~7% YoY; nutrition sales were weak (+4% YoY) but CGM product sales grew 17% YoY to $2.0 billion, and analysts (19 Buys vs. 4 Holds) see ~21% upside. Intuitive Surgical's preliminary Q4 results showed procedures +18% YoY and revenue +19% YoY to $2.87 billion, though 2026 procedure growth guidance of 13%–15% trails 2025's 18% pace; analyst positioning remains largely bullish (18 Buys, consensus ~16% upside). Both companies' upcoming official earnings releases could drive material stock moves depending on device/diagnostics momentum, China diagnostics recovery, and product launch traction in nutrition and imaging pipelines.

Analysis

Market structure: Device and procedural exposures (ISRG, ABT medical devices, CGM franchises) are the primary beneficiaries as procedures and device adoption accelerate; consumer nutrition and China-exposed diagnostics (Abbott’s nutrition unit, China diagnostics channels) are clear near-term losers. Expect modest re-pricing of market share toward high-growth procedure players over 3–12 months and temporary margin compression in China-exposed diagnostics until tariff/resolution clarity; option implied vol will spike ahead of late‑Jan earnings for ABT/ISRG, increasing hedging costs.

Risk assessment: Tail risks include an FDA safety restriction on robotic systems or a sudden China tariff escalation materially reducing diagnostics revenue (>5% FY impact) — both low probability but >20% P&L shock for affected lines. Immediate (days): earnings-driven IV and price moves; short-term (weeks/months): guidance revisions and product launch uptake; long-term (quarters/years): procedure secular growth and new therapeutics pipeline realization. Hidden dependency: hospital capex cycles and reimbursement policy can mute device adoption even with clinical demand.

Trade implications: Direct plays — establish directional exposure to ISRG and selective exposure to ABT’s device/diagnostics businesses while hedging China/nutrition risk. Use pair trades (long ISRG / short IHI equal dollar) to isolate company-specific upside over 3–12 months. Options: buy 9–12 month LEAPS on ISRG to capture secular growth, and use 45–90 day call spreads on ABT around earnings to limit premium spent.

Contrarian angles: Consensus underestimates upside from ISRG’s imaging/drug pipeline and Abbott’s potential nutrition re-acceleration from product relaunches; market may be over-penalizing near-term China noise. Historical parallel: device leaders have produced >25% returns in 12 months after similar guidance-driven sell-offs when fundamentals stayed intact. Unintended consequence: being long devices increases exposure to regulatory headlines; size positions accordingly.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in ISRG via 12-month LEAPS (target ~9–12 month horizon) to capture secular procedure growth; add if Q4 revenue beats by ≥2% or worldwide procedure growth guidance stays ≥13%.
• Establish a 2% tactical long in ABT focused on device/diagnostics exposure using a 45–90 day call spread into earnings to limit premium; convert to shares on a post-earnings pullback >5% if guidance on nutrition remains weak but devices/CGM show ≥15% YOY growth.
• Implement a relative-value pair: long ISRG / short equal-dollar IHI (or large-cap medical device ETF) sized 1–2% net exposure for 3–12 months to isolate ISRG idiosyncratic upside versus sector risk.
• Reduce/avoid direct exposure (>50% cut) to pure-play nutrition and China-diagnostics names; sell or hedge positions that derive >15% revenue from Chinese diagnostics until tariff/resolution clarity (monitor PRC trade announcements in next 30–60 days).
• Buy short-term (30–60 day) protective puts on device holdings sized to limit downside to 6–8% around earnings windows if implied volatility rises >30% above 90‑day average; otherwise use collars to fund protection.